CAR T cell immunotherapy emerged in the last decade as another exciting treatment option for high-risk relapsed/refractory CLL patients resistant to other treatments and bearing complex karyotypes and/or TP53 abnormalities [11]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.